Navigation Links
Labopharm Reports Results for Third Quarter Fiscal 2007
Date:11/9/2007

s marketing partner, Paladin Labs Inc., launched once-daily tramadol in Canada under the brand name Tridural(TM). The Company also completed licensing and distribution agreements for once-daily tramadol for South Korea with WhanIn Pharmaceutical Co., Ltd., for Greece with Lavipharm S.A. and for Israel with Dexcel Pharma Technologies Ltd. Labopharm expects its product to be launched in the South Korean and Greek markets in 2008. Labopharm's formulation is currently under regulatory review in Israel and the Company expects a response from the Israeli regulatory authority by mid-2008.

To date, Labopharm has secured marketing partners for its once-daily tramadol in more than 50 countries worldwide and regulatory approval in 25 countries. The Company's partners will continue to launch its product in additional markets, globally, throughout 2008.

In the U.S., Labopharm continues to vigorously pursue regulatory approval of its once-daily tramadol, appealing the U.S. Food and Drug Administration's (FDA) decision in its Approvable Letter through initiation of the Agency's Formal Dispute Resolution process. The Company believes that it has met the statutory standards for approval of its formulation and that appealing the FDA's decision through this process represents its best opportunity to expeditiously resolve this matter.

---------------------------------

(1) Labopharm's target market consists of the market for

immediate-release, twice-daily, once-daily and drop formulations of

tramadol.

(2) Includes France, Germany, the United Kingdom, Spain and Italy.

Once-Daily Trazodone Development Program

Labopharm has completed patient enrolment in its North American Phase III clinical trial for its once-daily formulation of the antidepressant trazodone, ahead of schedule. More than 400 patients are enrolled in the study.

"Our once-daily formulation represents the opportunity to address significant unmet needs in t
'/>"/>

SOURCE Labopharm Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

Related medicine news :

1. Labopharm To Present Poster On Onset Of Analgesic Effect Of Once-Daily Tramadol At Congress Of The European Society Of Regional Anaesthesia And Pain Therapy
2. Labopharm provides update on U.S. regulatory process for once-daily Tramadol
3. Labopharm completes enrolment for Phase III clinical study for its once-daily trazodone antidepressant drug
4. Labopharm appeals FDAs decision on once-daily tramadol
5. Labopharm to host conference call Friday, November 9, 2007 at 8:30 a.m. (ET)
6. Labopharm to present at CIBC World Markets 18th Annual Healthcare Conference
7. New Study Reports High Injury Rates for Hotel Workers, Even Higher Rates for Women and Nonwhites
8. Haemacure Reports Third Quarter 2007 Results
9. First-Ever List of the 5,000 Fastest-Growing Businesses Reports Total Revenue of $194.5 Billion
10. Consumer Reports Analysis: Drugs for Nerve Pain, Fibromyalgia Effective, But Not Always Best
11. MDS Reports Third Quarter 2007 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/12/2014)... Recently, iFitDress.com, one of the world’s leading ... red evening gowns . What’s more, all these hot outfits ... The company’s senior spokesman states, “We are proud to announce ... is an enjoyable shopping experience. In addition to the big ... low prices do not always mean bad quality. All the ...
(Date:7/12/2014)... 2014 Fresh off their respective performances in ... meet on September 5th at Sun Life Stadium in an ... some of the brightest stars in the world of football ... will be treated to some of the best talent in ... as the third best team in the world according to ...
(Date:7/12/2014)... By Dennis Thompson ... -- There,s no way to guarantee that a surgical technique ... tiny incisions won,t increase the risk of spreading cancer to ... Friday. The advisory panel to the Food and Drug ... -- called laparoscopic power morcellation -- should sign a written ...
(Date:7/12/2014)... Demand Response Management Systems is a ... reducing the imbalance between energy supply and demand. With ... rolled out (due to increasing pressure on the grid) ... in controlling residential appliances and thermostats for load reduction. ... American region, and with government mandates and benefits for ...
(Date:7/12/2014)... July 12, 2014 Tylenol lawsuits ... to move forward in the federal multidistrict litigation ... Pennsylvania, Bernstein Liebhard LLP reports. According to a ... Lawrence F. Stengel has ordered the deposition of ... Stengel found that the witness’s testimony concerning the ...
Breaking Medicine News(10 mins):Health News:Discounted Red Evening Gown Announced by iFitDress.com 2Health News:Brazil Vs. Colombia Tickets Sun Life Stadium: Ticket Down Slashes Ticket Prices for Friendly Match Between Colombia and Brazil 2Health News:Brazil Vs. Colombia Tickets Sun Life Stadium: Ticket Down Slashes Ticket Prices for Friendly Match Between Colombia and Brazil 3Health News:FDA Advisers Weigh Risks of Procedure for Removal of Uterine Fibroids 2Health News:FDA Advisers Weigh Risks of Procedure for Removal of Uterine Fibroids 3Health News:North America Demand Response Management System Worth $12,522.4 Million by 2019 - New Report by MicroMarket Monitor 2Health News:North America Demand Response Management System Worth $12,522.4 Million by 2019 - New Report by MicroMarket Monitor 3Health News:North America Demand Response Management System Worth $12,522.4 Million by 2019 - New Report by MicroMarket Monitor 4Health News:Tylenol Lawsuit News: U.S. District Judge Overseeing Federal Tylenol Liver Damage Litigation Orders Deposition of Former McNeil President, Bernstein Liebhard LLP Reports 2Health News:Tylenol Lawsuit News: U.S. District Judge Overseeing Federal Tylenol Liver Damage Litigation Orders Deposition of Former McNeil President, Bernstein Liebhard LLP Reports 3Health News:Tylenol Lawsuit News: U.S. District Judge Overseeing Federal Tylenol Liver Damage Litigation Orders Deposition of Former McNeil President, Bernstein Liebhard LLP Reports 4
... , SEATTLE, June 24 Lightspeed Design, Inc. announces ... software for state-of-the-art capture and playback of HD 3D ... hundreds of professional clients in corporate, entertainment, medical and ... into the new DepthQ(R) family of stereoscopic software -- ...
... , Pig jaw workshop gives attendees hands-on experience , ... RIEMSER , a leading manufacturer of bone tissue regeneration ... grafting workshop to be held in Chicago Friday, July 24th ... step-by-step instructions in site preservation, information on bone grafting materials ...
... doubt on notion of moms, unconditional love , ... likely than men to look away from less-than-cute babies, ... a mother,s unconditional love. , The findings might reflect ... healthy offspring, suggest the researchers, from Harvard-affiliated McLean Hospital ...
... OPEN NEXT SPRING IN HOUSTON METROPOLITAN AREA ... Living, Inc. (OTC Bulletin Board: TCSR), which develops, manages and ... a funding agreement with a national lender for the development ... metropolitan area. Funding for Trinity Terrace , an ...
... of Phosphatidylserine-Targeting Antibodies to Image Solid Tumors and Other Malignancies ... Showing Utility of PS-Targeting Antibodies for the Molecular Imaging of ... Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM ) today reported ... vascular imaging applications for phosphatidylserine (PS)-targeting antibodies. The patent ...
... Seventy-Seven Percent of Surveyed Physicians Will Increase Their Use ... a New Report from AMR and Decision Resources , ... /PRNewswire/ -- Arlington Medical Resources (AMR) and ... oral formulation is a leading drug attribute that surveyed ...
Cached Medicine News:Health News:Lightspeed Releases the New DepthQ(R) Family of Stereoscopic HD Video Software 2Health News:Lightspeed Releases the New DepthQ(R) Family of Stereoscopic HD Video Software 3Health News:RIEMSER Announces Upcoming Chicago Bone Grafting Workshop 2Health News:Women More Likely Than Men to Reject Unattractive Babies 2Health News:TrinityCare Senior Living Announces Funding Agreement for Fourth Senior Living Facility 2Health News:Peregrine Pharmaceuticals Awarded Broad New U.S. Patent for Vascular Imaging Applications of Its PS-Targeting Platform 2Health News:Peregrine Pharmaceuticals Awarded Broad New U.S. Patent for Vascular Imaging Applications of Its PS-Targeting Platform 3Health News:Peregrine Pharmaceuticals Awarded Broad New U.S. Patent for Vascular Imaging Applications of Its PS-Targeting Platform 4Health News:Availability in Both Intravenous and Oral Formulation is a Leading Drug Attribute Surveyed Physicians Prefer for the Treatment of Urinary Tract Infections in the Hospital Setting 2Health News:Availability in Both Intravenous and Oral Formulation is a Leading Drug Attribute Surveyed Physicians Prefer for the Treatment of Urinary Tract Infections in the Hospital Setting 3
(Date:1/15/2014)... Most osteoporosis patients want a choice in the medication ... by Mission Pharmacal Company. The survey, conducted by ... community, revealed that 74 percent of osteoporosis patients surveyed ... other than a pill or a tablet. ...
(Date:1/15/2014)... AARP Foundation today announced it has established a ... severe cold weather that has gripped much of the nation. ... need; so to support these emergency relief efforts AARP and ... could mean up to $500,000 in aid. The matching program ...
(Date:1/15/2014)... THOUSAND OAKS, Calif. , Jan. 15, 2014 ... and Amgen (NASDAQ: AMGN ) announced ... to jointly discover and validate new therapeutic targets ... (IBD), a chronic disorder that affects millions worldwide. ...
Breaking Medicine Technology:Mission Pharmacal Conducts Online Survey of Osteoporosis Patients 2Mission Pharmacal Conducts Online Survey of Osteoporosis Patients 3AARP Foundation Establishes Winter Relief Fund for Older Adults Suffering from the Severe Cold Weather 2AARP Foundation Establishes Winter Relief Fund for Older Adults Suffering from the Severe Cold Weather 3Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 2Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 3Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 4
... 2011 Mylan Inc. (Nasdaq: MYL ) ... announced refinancing of its existing secured credit facility. The ... upsized from the originally planned $2.25 billion and comprises ... billion Term Loan A facility. The proceeds were used ...
... CLEVELAND and GAITHERSBURG, Md., Nov. 14, 2011 University ... School of Medicine and Lentigen Corporation announced today the ... LG631 gene therapy for the protection of hematopoietic stem ... with Temodar.   Approximately 17,000 Americans are ...
Cached Medicine Technology:Mylan Successfully Upsizes and Completes Refinancing of Credit Facility 2Lentigen and UH Case Medical Center Initiate Phase I Trial Using Gene Therapy and Bone Marrow Stem Cells in the Treatment of Brain Cancer 2Lentigen and UH Case Medical Center Initiate Phase I Trial Using Gene Therapy and Bone Marrow Stem Cells in the Treatment of Brain Cancer 3Lentigen and UH Case Medical Center Initiate Phase I Trial Using Gene Therapy and Bone Marrow Stem Cells in the Treatment of Brain Cancer 4
Interchangeable design allows you to select a single handpiece and change tips during the procedure. Universal connector. Disassembles for easy cleaning. Tips can rotate 360 degrees to re-orient port...
Infusion Cannula, 6.0mm....
Subretinal Injection Cannula, Curved; 20g (0.90) x 1" (25mm); Tip Extension: 3mm, 32g (0.23); Angled at 35°....
Injection Cannula, Angled; 20g (0.90) x 1" (25mm); Tip Extension: 5mm, 30g (0.30); Angled at 45°, 2.5mm from Tip....
Medicine Products: